Aridis to participate in key opinion leader discussion on immunotherapy for infectious diseases

Los gatos, calif., nov. 22, 2022 (globe newswire) -- aridis pharmaceuticals, inc. (nasdaq: ards) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced its participation in h.c. wainwright & co.'s 2022 kol series (part 8) on tuesday, november 29, at 11 a.m. est. the kol event will focus on the use of monoclonal antibody-based immunotherapies in infectious diseases and aridis' phase 3 ‘asap-1' study that compares the superiority of adjunctive use of the investigational, targeted immunotherapy candidate ar-301 with standard of care (soc) antibiotics versus soc antibiotics alone, for the treatment of ventilator associated pneumonia (vap) caused by gram-positive bacteria staphylococcus aureus (s. aureus).
ARDS Ratings Summary
ARDS Quant Ranking